Skip to main content
  • AACR Journals
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Molecular Targets Collections
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Journals
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Molecular Targets Collections
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Research Article

APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency

Cheng-Yu Tsai, Si Sun, Hongying Zhang, Andrea Local, Yongxuan Su, Larry A Gross, William G. Rice and Stephen B. Howell
Cheng-Yu Tsai
Moores Cancer Center, University of California, San Diego
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Si Sun
Moores Cancer Center, University of California, San Diego
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongying Zhang
Aptose Biosciences, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Local
Aptose Biosciences, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongxuan Su
Department of Chemistry and Biochemistry, University of California, San Diego
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Larry A Gross
Department of Chemistry and Biochemistry, University of California, San Diego
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William G. Rice
Aptose Biosciences, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen B. Howell
Moores Cancer Center, University of California, San Diego
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: showell@ucsd.edu
DOI: 10.1158/1535-7163.MCT-17-0834
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Additional Files

  • Supplementary Data

    • Supplementary Material - Chemical Synthesis of APTO-253
    • Figure S1 - Influx and efflux of APTO-253 and Fe(253)3.
    • Figure S2 - The accumulation of phospho-ATM, γ-H2AFX and cleaved PARP in Raji compared to that in Raji/253R cells exposed to APTO-253 for 24 h.
    • Figure S3 - Role of ABCG2 in resistance to Fe(253)3.
    • Table S1 - Rate of efflux of APTO-253 and Fe(253)3 from Raji and Raji/253R cells over first 2 hours (log fmole/10^7 cells/h)
    • Table S2 - Rank order of genes up-regulated in Raji/253R cells.
    • Table S3 - ABC transporter family member genes up-regulated in Raji/253R cells
    PreviousNext
    Back to top

    Published OnlineFirst April 16, 2018
    doi: 10.1158/1535-7163.MCT-17-0834

    Open full page PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for sharing this Molecular Cancer Therapeutics article.

    NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

    Enter multiple addresses on separate lines or separate them with commas.
    APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency
    (Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
    (Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
    Citation Tools
    APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency
    Cheng-Yu Tsai, Si Sun, Hongying Zhang, Andrea Local, Yongxuan Su, Larry A Gross, William G. Rice and Stephen B. Howell
    Mol Cancer Ther April 16 2018 DOI: 10.1158/1535-7163.MCT-17-0834

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency
    Cheng-Yu Tsai, Si Sun, Hongying Zhang, Andrea Local, Yongxuan Su, Larry A Gross, William G. Rice and Stephen B. Howell
    Mol Cancer Ther April 16 2018 DOI: 10.1158/1535-7163.MCT-17-0834
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
    • Figures & Data
    • Info & Metrics
    • PDF
    Advertisement

    Related Articles

    Cited By...

    More in this TOC Section

    • Induction of telomere damage to treat pediatric brain tumors
    • A synthetic BRCA2 peptide inhibits RAD51
    Show more Research Article
    • Home
    • Alerts
    • Feedback
    Facebook  Twitter  LinkedIn  YouTube  RSS

    Articles

    • Online First
    • Current Issue
    • Past Issues
    • Meeting Abstracts

    Info for

    • Authors
    • Subscribers
    • Advertisers
    • Librarians
    • Reviewers

    About MCT

    • About the Journal
    • Editorial Board
    • Permissions
    • Submit a Manuscript
    AACR logo

    Copyright 2016 by the American Association for Cancer Research.

    Molecular Cancer Therapeutics
    eISSN: 1538-8514
    ISSN: 1535-7163

    Advertisement